Skip to content
AbTis | 앱티스 logo — Bridging Life and Science with Innovative Linker Technology

AbTis | 앱티스

Bridging Life and Science with Innovative Linker Technology

Founded 2016 Korea South Korea South 11 employees Series B Total: $15.00B Biotechnology, Health Care +1

General Information

Company Name AbTis | 앱티스
Founded Year 2016
Location Korea South Korea South
Employees 11
Industries Biotechnology, Health Care, Medical Devices
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with AbTis | 앱티스. To contact AbTis | 앱티스, visit abtis.co.kr.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does AbTis | 앱티스 compare?

A PDF of AbTis | 앱티스 and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting AbTis | 앱티스 soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About AbTis | 앱티스

AbTis Co., Ltd. is a leading ADC Biotech Company based in Korea South, founded in 2016. Known for its slogan "ADC 플랫폼 및 파이프라인 개발" which translates to "ADC platform and pipeline development," the company boasts of world-class platform technology. In its latest funding round, AbTis Co., Ltd. secured a significant KRW15.00B Series B investment on 02 February 2021. This substantial investment was backed by a group of prominent investors including Aju IB Investment, K2 Investment Partners, Prodigy Investment, Stonebridge Ventures, Timefolio Asset Management, Kingo Investment Partners, and KDB Industrial Bank.

Specializing in the Biotechnology and Health Care industries, AbTis Co., Ltd. is dedicated to advancing the field of ADC biotechnology. With its strong financial backing and a clear focus on groundbreaking technology, the company is well-positioned to make a significant impact in the biotech sector and beyond.

Business keywords: ADC, biotech, platform technology, drug development, pharmaceuticals, innovation, biopharmaceuticals, targeted therapies

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series B KRW15.00B 7
Aju IB Investment, K2 Investment Partners +5
02 Feb 2021

AbTis | 앱티스 Alternatives & Competitors

View All Alternatives
AbTis | 앱티스 vs

Accelerating solutions for developers to overcome conjugation challenges, making new ADC-based anti-...

Venture round
Biopharma, Biotechnology
AbTis | 앱티스 vs

A New Generation Biotech Company

Grant
8 employees
Biotechnology, Health Care
AbTis | 앱티스 vs

Next generation antibody drug conjugates

Series C
48 employees
Biotechnology, Health Care

FAQ About AbTis | 앱티스

Bridging Life and Science with Innovative Linker Technology
AbTis | 앱티스 was founded in 2016.
AbTis | 앱티스 is headquartered in Korea South.
AbTis | 앱티스 operates in Biotechnology, Health Care and Medical Devices. Its work centres on ADC, biotech, platform technology and drug development.
AbTis | 앱티스 has approximately 11 employees.
AbTis | 앱티스 has completed 1 funding round, raising a total of $15.00B. The latest funding stage is Series B.
Top alternatives and competitors to AbTis | 앱티스 include ADC Biotechnology, ABIONYX Pharma, NBE-Therapeutics AG, Prescient Therapeutics, Ablexis, LLC. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AbTis | 앱티스 and ADC Biotechnology are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for AbTis | 앱티스, https://bouncewatch.com/company/abtis-co-ltd, updated 14 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout